NCT02871570

A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

A Phase 1, Non-randomized, Open-label, Parallel-group Single-dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Intravenous Rivipansel (Pf-06460031) In Subjects With Moderate Hepatic Impairment And In Healthy Subjects With Normal Hepatic Function

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: GlycoMimetics Incorporated · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine the effect of hepatic impairment on rivipansel PK and safety.

Conditions

• Moderate Hepatic Impairment
• Normal Hepatic Function

Interventions

Type	Name	Description
DRUG	Rivipansel	A single dose of IV Rivipansel over 20 minutes

Timeline

• Start date: 2016-09-01
• Primary completion: 2017-02-01
• Completion: 2017-03-01
• First posted: 2016-08-18
• Last updated: 2020-07-09
• Results posted: 2018-11-28

Locations

1 site across 1 country: United States